Contrasting Catalyst Biosciences (CBIO) & Avid Bioservices (CDMO)

Catalyst Biosciences (NASDAQ: CBIO) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Profitability

How to Become a New Pot Stock Millionaire

This table compares Catalyst Biosciences and Avid Bioservices’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalyst Biosciences -2,117.98% -93.68% -62.75%
Avid Bioservices -46.62% -57.49% -28.83%

Analyst Ratings

This is a breakdown of current ratings and price targets for Catalyst Biosciences and Avid Bioservices, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalyst Biosciences 0 0 3 0 3.00
Avid Bioservices 0 0 3 0 3.00

Catalyst Biosciences presently has a consensus target price of $45.00, indicating a potential upside of 62.34%. Avid Bioservices has a consensus target price of $7.00, indicating a potential upside of 170.27%. Given Avid Bioservices’ higher probable upside, analysts plainly believe Avid Bioservices is more favorable than Catalyst Biosciences.

Risk and Volatility

Catalyst Biosciences has a beta of 2.58, suggesting that its share price is 158% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Institutional & Insider Ownership

26.5% of Catalyst Biosciences shares are held by institutional investors. Comparatively, 14.7% of Avid Bioservices shares are held by institutional investors. 5.0% of Catalyst Biosciences shares are held by company insiders. Comparatively, 2.5% of Avid Bioservices shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Catalyst Biosciences and Avid Bioservices’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Catalyst Biosciences $1.02 million 298.13 -$21.56 million ($9.40) -2.95
Avid Bioservices $57.63 million 2.50 -$28.15 million ($0.81) -3.20

Catalyst Biosciences has higher earnings, but lower revenue than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than Catalyst Biosciences, indicating that it is currently the more affordable of the two stocks.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Avid Bioservices Company Profile

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply